← Back to Search

Dietary Supplement

Casein glycomacropeptide (CGMP) for Irritable Bowel Syndrome

N/A
Waitlist Available
Research Sponsored by Oregon State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, gmp feeding week 1, 2 and 3 and post study without gmp feeding week 1, 2 and 3
Awards & highlights

Study Summary

This trial looks at using GMP to change the gut microbiome, metabolome, and protein profile in people with IBS.

Eligible Conditions
  • Irritable Bowel Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, gmp feeding week 1, 2 and 3 and post study without gmp feeding week 1, 2 and 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, gmp feeding week 1, 2 and 3 and post study without gmp feeding week 1, 2 and 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure the inflammatory markers in stool and blood using immunology multiplex assay
Stool sample based gut microbiome composition using 16S rRNA gene sequencing

Trial Design

1Treatment groups
Experimental Treatment
Group I: Casein glycomacropeptide (CGMP)Experimental Treatment1 Intervention
The subjects will receive a daily oral intake of CGMP-protein-shake for 3 weeks with a 1 week wash-in and a 3 week wash-out. Intervention: Dietary Supplement: Casein glycomacropeptide (CGMP)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Casein glycomacropeptide (CGMP)
2022
N/A
~100

Who is running the clinical trial?

Oregon State UniversityLead Sponsor
49 Previous Clinical Trials
8,366 Total Patients Enrolled
BUILD DairyUNKNOWN
1 Previous Clinical Trials
90 Total Patients Enrolled
AgropurUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I able to register for this medical experiment?

"This clinical trial is accepting 15 participants aged 18-30 with inflammatory bowel disease who fulfill the criteria of fluency in English, a diagnosis which meets Rome IV standards, and having a primary care physician."

Answered by AI

How many participants can join this trial?

"Affirmative. Clinicaltrials.gov provides evidence that this investigation is currently recruiting participants, with the original post date being January 1st 2022 and a recent update on July 28th 2022. The study requires 15 patients to be recruited from one site."

Answered by AI

Does the research include elderly participants over 70 years of age?

"Patients aged between 18 to 30 years old are qualified for this clinical trial. Alternatively, there are 379 and 1007 studies available respectively for minors and seniors above the age of 65."

Answered by AI

Is enrollment available to participants at this point in time?

"Yes, according to clinicaltrials.gov the trial is still recruiting volunteers as of July 28th 2022. The study was initially listed on January 1st and requires 15 participants from a single location."

Answered by AI

Who else is applying?

What state do they live in?
Washington
Illinois
Kentucky
What site did they apply to?
Milam Hall, Room 001
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

I have tried everything available on the market.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

How long will it last?
PatientReceived 2+ prior treatments

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Milam Hall, Room 001: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
Dave Dallas 2022. "Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05482464.
~2 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top